Program
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363
Also written as “IBI363”, “IBI363 + bevacizumab” and “IBI363+IBI305”.
Its studies are mostly in Melanoma · Lymphoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Ovarian Neoplasms, led by Innovent Biologics.
Drug pageAnti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 1010 open or running | phase 3since Jul 20, 2026 | Jan 9, 2022 | Nov 30, 2026phase 2 · NCT07122687 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2022First study: phase 1 study in LymphomaFirst studyNCT05290597 · 40 enrolled · Australia
- Jul 5, 2022Phase 1 study in LymphomaNCT05460767 · 504 enrolled · China
- Oct 7, 2023Phase 2 study in MelanomaNCT06081920 · 180 planned · China
- Feb 4, 2024Phase 2 study in MelanomaNCT06281678 · 178 planned · United States
- Jun 13, 2024Phase 1 study in Advanced MalignanciesNCT06468098 · 556 planned · China
- Jan 22, 2025Phase 2 study in MelanomaNCT06797297 · 203 enrolled · China
- Jun 24, 2025Phase 2 study in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerNCT07122687 · 170 planned · China
- Aug 7, 2025Phase 2 study in EGFR Mutant NSCLC and Platinum Resistant Ovarian CancerNCT07124793 · 60 planned · China
- Jan 16, 2026Phase 2 study in Resectable Stage II-III Non-small Cell Lung CancerNCT07402070 · 10 planned · China
- Jul 20, 2026Phase 3 study in Colorectal NeoplasmsPhase 3 reachedNCT07722494 · 550 planned · China
- Nov 2, 2026Primary completion moved from 2026-03-31 to 2026-12-31Date moved laterphase 2 · +9 months · NCT06797297
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerNCT07122687
- Dec 31, 2026Primary completion: phase 2 study in Resectable Stage II-III Non-small Cell Lung CancerNCT07402070
- Dec 31, 2026Primary completion: phase 2 study in MelanomaNCT06797297
- Dec 31, 2026Primary completion: phase 1 study in LymphomaNCT05460767
TargetBeta
“A bispecific antibody fusion protein composed of a monoclonal antibody targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and ”NCIt, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
| sasanlimab | Pfizer | phase 3 | 4 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722494Colorectal Neoplasms · China | 3 | Recruiting | Oct 31, 2028 | 550 |
| NCT07402070Resectable Stage II-III Non-small Cell Lung Cancer · China | 2 | Not yet recruiting | Dec 31, 2026 | 10 |
| NCT07124793EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer · China | 2 | Not yet recruiting | Sep 30, 2026 | 60 |
| NCT07122687Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer · China | 2 | Recruiting | Nov 30, 2026 | 170 |
| NCT06797297Melanoma · China | 2 | Active, not recruiting | Dec 31, 2026 | 203 |
| NCT06468098Advanced Malignancies · China | 1 | Recruiting | Jun 30, 2025 | 556 |
| NCT06281678Melanoma · United States | 2 | Recruiting | Mar 1, 2026 | 178 |
| NCT06081920Melanoma · China | 2 | Recruiting | Oct 19, 2028 | 180 |
| NCT05460767Lymphoma · China | 1 | Active, not recruiting | Dec 31, 2026 | 504 |
| NCT05290597Lymphoma · Australia | 1 | Active, not recruiting | Jan 28, 2026 | 40 |
How it is read
Names in the registry
- “IBI363”, 7 entries
- “IBI363 + bevacizumab”, 1 entry
- “IBI363+IBI305”, 1 entry
- “IBI363 + chemotherapy”, 1 entry
- “IBI363 + Investigator's Choice SOC”, 1 entry
Codes read as this program: IBI363.
Conditions, from the studies’ own filings
- Melanoma, 3 studies
- Lymphoma, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Colorectal Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.